Показати скорочений опис матеріалу
dc.contributor.author | Gai, L. | en |
dc.contributor.author | Hruzevskyi, O. | en |
dc.contributor.author | Koltsova, I. | en |
dc.contributor.author | Dubina, A. | en |
dc.contributor.author | Tabulina, A. | en |
dc.date.accessioned | 2024-06-17T11:35:09Z | |
dc.date.available | 2024-06-17T11:35:09Z | |
dc.date.issued | 2024 | |
dc.identifier.citation | The use of immunological drugs for the treatment of wound infections in military personnel during hostilities / L. Gai, O. Hruzevskyi, I. Koltsova et al. // Future Med. 2024. No. 3 (1). P. 59–70. | en |
dc.identifier.uri | https://repo.odmu.edu.ua:443/xmlui/handle/123456789/15523 | |
dc.description.abstract | Aims: To assesses the trends in immunological drug development for managing wound infections in military personnel. To discuss the efficacy, safety, and long-term results, focusing on combination therapies, and identifying research deficits for improving the care of military wounds. Methodology: A narrative review was used in order to explores the use of immunological drugs for treating wound infections in military settings utilising a search strategy identified 840 publications from PubMed, with 6 studies meeting inclusion criteria for analysis from the years 2019 to 2022. Results: The narrative review concerning the use of immunological drugs for treating wound infections in military personnel during hostilities revealed an increasing trend in research interest from 2000 to 2024, with a significant rise from 7 publications in 2000 and 2001 to a peak of 72 in 2018, followed by a descent to 19 in 2021 likely due to the COVID-19 pandemic, and a slight recovery to 41 in 2022. The key findings included a 50% reduction in infection rates and a 30% faster healing time with monoclonal antibody treatments, over 95% accuracy in species identification of MDR strains, and reduced bacteremia incidence with GM-CSF and G-CSF. Adverse effects varied from mild to moderate, including infusion reactions, nausea, and fatigue. The highlighted challenges included the need for larger sample sizes, long-term follow-up, optimal dosages, and studying diverse populations. Scientific Novelty: Explore the innovative realm of immunological drugs, a promising frontier in combating wound infections among military personnel during active hostilities. Conclusion: The review also identified new developments in immunomodulatory agents for military wound infection, which are effective in decreasing infection rates and enhancing the rate of wound healing. | en |
dc.language.iso | en | en |
dc.subject | wound infections | en |
dc.subject | military personnel | en |
dc.subject | hostilities | en |
dc.subject | immunological drugs | en |
dc.subject | treatment | en |
dc.title | The use of immunological drugs for the treatment of wound infections in military personnel during hostilities | en |
dc.type | Article | en |